Cost Effectiveness of TNF-𝛼 Inhibitors in Rheumatoid Arthritis

Table 2

Analysis of SF-36 scores.

SF-36 domain	Phase	Difference in mean (%)	P value*
Physical function (PF)	Phase 1-Phase 2	36.54	0.00
	Phase 1-Phase 3	38.46	0.00
	Phase 2-Phase 3	1.92	0.96
Physical role (PR)	Phase 1-Phase 2	69.23	0.00
	Phase 1-Phase 3	73.08	0.00
	Phase 2-Phase 3	3.85	0.94
Emotional role (ER)	Phase 1-Phase 2	64.07	0.00
	Phase 1-Phase 3	79.46	0.00
	Phase 2-Phase 3	15.40	0.20
Bodily pain (BP)	Phase 1-Phase 2	51.62	0.00
	Phase 1-Phase 3	58.62	0.00
	Phase 2-Phase 3	7.00	0.48
Vitality (V)	Phase 1-Phase 2	41.92	0.00
	Phase 1-Phase 3	44.23	0.00
	Phase 2-Phase 3	2.31	0.85
Social functioning (SF)	Phase 1-Phase 2	54.81	0.00
	Phase 1-Phase 3	56.73	0.00
	Phase 2-Phase 3	1.92	0.93
Mental health (MH)	Phase 1-Phase 2	32.62	0.00
	Phase 1-Phase 3	34.15	0.00
	Phase 2-Phase 3	1.54	0.97
General health (GH)	Phase 1-Phase 2	25.08	0.00
	Phase 1-Phase 3	26.85	0.00
	Phase 2-Phase 3	1.77	0.90

The difference in mean scores obtained between phases for every SF-36 domain and their relative level of significance (significance noted at 𝑃<0.05*).